On November 4, 2025, the White House issued an order to modify the additional tariff duties on products imported from the People’s Republic of China (PRC) in relation to the ongoing opioid crisis. The tariff, originally set at 20 percent, will be reduced to 10 percent effective November 10, 2025, following commitments from the PRC to address the trafficking of synthetic opioids to the U.S. This reduction responds to discussions highlighting the PRC’s intentions to implement measures aimed at controlling chemical exports linked to fentanyl production, a significant threat to U.S. public health and safety.

The initial declaration of a national emergency regarding the synthetic opioid supply chain was made in February 2025, citing the substantial threat posed by the PRC’s failure to address this issue. The increasing influx of synthetic opioids has been classified as an unusual and extraordinary threat to national security, leading to a series of executive orders designed to compel action from China. The latest order allows for ongoing monitoring and potential adjustments to the tariff structure based on the PRC’s compliance with its commitments and progress in alleviating the drug crisis.

Additionally, the order empowers the Secretary of Homeland Security to oversee compliance and recommend further actions if necessary. This ongoing scrutiny and engagement highlight the U.S. government’s commitment to mitigating the effects of the opioid epidemic through international cooperation and trade policy adjustments. Overall, the modification reflects an evolving diplomatic approach focused on shared responsibilities in addressing the challenges posed by synthetic opioids.

Original: article